Telomir Pharmaceuticals (TELO) said Wednesday that preclinical findings showed that Telomir-1 reduces tumor size by 50% in a prostate cancer animal model using "highly aggressive" human prostate cancer cells.
Telomir-1 "actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel," a chemotherapy drug that is often linked with severe toxicity and side effects, the company said.
Telomir said it is advancing Telomir-1 in several indications in addition to oncology. Studies are assessing the drug in age-related diseases like age-related macular degeneration and Wilson's disease, the company said.
The company said it plans to file an investigational new drug application by the end of the year.
Telomir shares were up 4% in recent Wednesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。